MétaCan
Menu
Retour à la cohorte
Enregistrement W3164869391 · doi:10.1016/j.mayocpiqo.2021.05.004

Patient Satisfaction of Telemedicine Visits in an Advanced Prostate Cancer Clinic During the COVID-19 Pandemic

2021· article· en· W3164869391 sur OpenAlexaboutno aff
Mohamed E. Ahmed, Jack R. Andrews, Vidhu B. Joshi, Lance A. Mynderse, Matthew K. Tollefson, R. Jeffrey Karnes, Eugene D. Kwon

Notice bibliographique

RevueMayo Clinic Proceedings Innovations Quality & Outcomes · 2021
Typearticle
Langueen
DomaineMedicine
ThématiqueCOVID-19 and healthcare impacts
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésTelemedicineMedicineScopusPandemicProstate cancerCoronavirus disease 2019 (COVID-19)Family medicinePublic healthCancerPopulationHealth careMEDLINEInternal medicineNursingEnvironmental healthDiseasePolitical science

Résumé

récupéré en direct d'OpenAlex

Telemedicine is the use of communication technologies to provide patient care remotely.1Field M.J. Telemedicine: A Guide to Assessing Telecommunications for Health Care. National Academies Press, Washington, DC1996Google Scholar Before March 2020, telemedicine was gaining attention in medicine, but widespread utilization was low. In March 2020, the global public health faced a crisis with the COVID-19 pandemic.2World Health OrganizationWHO Director-General's opening remarks at the media briefing on COVID-19—11 March 2020.https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020Date accessed: August 15, 2020Google Scholar Cancer patients in particular were at a higher risk of becoming infected and having severe complications.3Yu J. Ouyang W. Chua M.L. Xie C. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan.JAMA Oncol. 2020; 6: 1108-1110Crossref PubMed Scopus (789) Google Scholar Moreover, Montopoli et al4Montopoli M. Zumerle S. Vettor R. et al.Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532).Ann Oncol. 2020; 31: 1040-1045Abstract Full Text Full Text PDF PubMed Scopus (392) Google Scholar reported that prostate cancer patients were at an increased risk of severe acute respiratory syndrome coronavirus 2 infection and constituted 28% of COVID-19–positive cancer patients, followed by kidney/bladder cancer (17%) and colorectal cancer (15%). As a result of COVID-19 and the risks it posed to both patients and providers, a global decrease in urology service volumes was observed. According to an international multicenter survey of 1004 urology service providers in April 2020, 37% of respondents reported outpatient clinic volume reductions of between 81% and 100% and delays of more than 8 weeks in 28% of outpatient clinics.5Teoh J.Y. Ong W.L.K. Gonzalez-Padilla D. et al.A global survey on the impact of COVID-19 on urological services.Eur Urol. 2020; 78: 265-275Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar Given the significant risks to patients in our advanced prostate cancer clinic, we rapidly implemented telemedicine in our practice to continue care of oncology patients without jeopardizing the patients’ health. This use of telemedicine was ultimately consistent with guidelines released in 2020 on the management of prostate cancer during the COVID-19 pandemic, including avoiding in-person clinic visits.6Burki T.K. Cancer guidelines during the COVID-19 pandemic.Lancet Oncol. 2020; 21: 629-630Abstract Full Text Full Text PDF PubMed Scopus (227) Google Scholar, 7Obek C. Doganca T. Argun O.B. Kural A.R. Management of prostate cancer patients during COVID-19 pandemic.Prostate Cancer Prostatic Dis. 2020; 23: 398-406Crossref PubMed Scopus (35) Google Scholar, 8Kokorovic A. So A.I. Hotte S.J. et al.A Canadian framework for managing prostate cancer during the COVID-19 pandemic: recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association.Can Urol Assoc J. 2020; 14: 163-168Crossref PubMed Google Scholar, 9Gomez Rivas J. Dominguez M. Gaya J.M. et al.[Prostate cancer and COVID-19 pandemia: current recommendations.].Arch Esp Urol. 2020; 73: 367-373PubMed Google Scholar Herein, we report our patients’ telemedicine experience in an advanced prostate cancer clinic during the COVID-19 pandemic. Our advanced prostate cancer clinic at Mayo Clinic Rochester provides high-volume care to patients with advanced prostate cancer in a multidisciplinary approach that includes radiation therapy, surgery, and systemic treatments. The clinic serves approximately 5000 patients annually. We included advanced prostate cancer patients located in the United States who were seen by a single urologist (Dr Eugene D. Kwon ) through teleconsultation between April 1, 2020, and May 1, 2020, during the COVID-19 pandemic. Teleconsultation included phone visits and any form of video visits (Zoom, Skype, FaceTime, other). During April 2020, there were 350 scheduled in-person visits. Following the announcement of the national stay-at-home order due to the COVID-19 pandemic, patients were contacted and offered telemedicine consultations; 103 (30%) patients agreed to transition their next visit to teleconsultation with their physician to avoid any interruption of their care. These patients represented our target population (n=103). After their teleconsultation, patients were contacted by phone about participation in the study. Of 103 patients, 52 (50.49%) patients electronically signed the consent form and were sent a unique link to the Research Electronic Data Capture system (REDCap). Study data were recorded and managed using this system. We adopted a survey that has been used previously to assess telemedicine in radiation oncology.10Hamilton E. Van Veldhuizen E. Brown A. Brennan S. Sabesan S. Telehealth in radiation oncology at the Townsville Cancer Centre: service evaluation and patient satisfaction.Clin Transl Radiat Oncol. 2018; 15: 20-25Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar Some changes have been made to customize it to our study. Patients’ demographic and clinical characteristics are shown in Table 1. Most of the patients denied any hearing or vision difficulty. Almost 60% (n=31) of patients presented with progressive disease and rising prostate-specific antigen (PSA) concentration; the remaining 40% (n=21) returned to follow up on their treatment plans. Patients reported the average cost to travel for their appointment to be 250 (125 to 350) US dollars. Most of the telemedicine consultations were done over the phone (n=41; 78.85%) because of the patient’s accessibility, whereas the remaining (n=11; 21.15%) were done through Zoom video conference.Table 1Characteristics of Patients Responding to Our Telemedicine Survey (n=52)Age (y)70.40 (±8.06)Ethnicity White49 (94.23) Not Hispanic or Latino2 (3.85) Hispanic or Latino1 (1.92)Education level High-school diploma or less4 (7.69) College degree or less42 (80.77) Professional/doctorate degree6 (11.54)Marital status Married47 (90.39) Single2 (3.85) Widowed1 (1.92) Divorced2 (3.85)Occupation status Working19 (36.54) Retired33 (63.46)Previous experience with telemedicine Yes35 (67.31) No17 (32.69)Distance from Mayo Clinic (miles)410 (226.3-802.5)Will take a flight for their visits Yes17 (32.69) No35 (67.31)Will book a hotel for their visit Yes37 (71.15) No15 (28.85)Difficulty with hearing Yes12 (23.08) No40 (76.92)Difficulty with vision Yes6 (11.54) No46 (88.46)Values are reported as mean (±SD), number (%), or median (interquartile range). Open table in a new tab Values are reported as mean (±SD), number (%), or median (interquartile range). Before each virtual visit, patients were asked to undergo PSA testing with or without imaging for restaging purposes and localizing their disease relapse. Laboratory testing and imaging were completed either locally or at Mayo Clinic. With respect to PSA, 19% (n=10) of the patients were not able to undergo PSA testing before their virtual visit. Of those who completed PSA testing, 38.46% (n=20) and 32.69% (n=17) underwent testing at either Mayo Clinic laboratories or locally, respectively. The remaining 9.62% (n=5) of patients underwent previsit PSA testing through mail-in kit testing. With respect to imaging, most patients (n=32; 61.54%) underwent previsit imaging at Mayo Clinic, whereas 32.08% (n=12) underwent previsit imaging locally, and only 15.39% (n=8) were not able to undergo any forms of imaging before their virtual visit. Table 2 presents patients’ satisfaction with their telemedicine consultation. The Figure illustrates patients’ reported advantages of telemedicine consultations ranked from most important (1) to least important (4).Table 2Responses to Our Telemedicine Satisfaction SurveyItem No.StatementStrongly disagreeDisagreeNeutralAgreeStrongly agree21I could hear the doctor clearly.002 (3.85)14 (26.92)36 (69.23)22I felt my privacy and confidentiality were respected.002 (3.85)15 (28.85)35 (67.31)23I felt I could ask questions and seek clarification openly and easily with my doctor.001 (1.92)18 (34.62)33 (63.46)24I found it easy to establish rapport with my doctor.004 (7.69)14 (26.92)34 (65.39)26I felt my diagnosis and treatment options could be adequately explained.004 (7.69)18 (34.62)30 (57.69)27I felt my doctor spent an adequate amount of time to understand my condition and concerns.001 (1.92)21 (40.39)30 (57.69)28I would participate in a future teleconsultation if it were offered.03 (5.77)7 (13.46)17 (32.69)25 (48.08)Values are reported as number (%). Open table in a new tab Values are reported as number (%). In our experience, the use of telemedicine was effective in patients with advanced prostate cancer. It served as a means of continuing the patients’ care without endangering their health. Table 2 demonstrates that most patients agreed that they were able to hear (and see) their physician clearly, their privacy and confidentiality were respected, they were able to ask questions easily, and they were able to establish rapport with their doctor. All patients verified that their physician had adequately explained their diagnosis and treatment options and spent sufficient time to understand their condition and concerns. Therefore, 94% of the patients shared that they would participate in a future teleconsultation if it was offered. Interestingly, all of the remaining 6% (n=3) who would not participate in a future teleconsultation had a phone consultation. Furthermore, in the general comment section, they mentioned they would prefer video consultation in the future and felt uncomfortable not being able to see their physician. Patients reported that saving on travel (n=24) represented the most important advantage of having virtual consultations, followed by time savings (n=20) and cost savings and reduced family interruption (n=18 each; Figure). Therefore, in our experience, the use of telemedicine can provide uninterrupted care with a high level of patient satisfaction and with many potential advantages for the patient. The high level of patient satisfaction with telemedicine observed in our study is consistent with findings from a study by Leibar Tamayo et al11Leibar Tamayo A. Linares Espinos E. Rios Gonzalez E. et al.Evaluation of teleconsultation system in the urological patient during the COVID-19 pandemic.Actas Urol Esp. 2020; 44: 617-622Crossref PubMed Scopus (18) Google Scholar in which 200 patients were surveyed on their telemedicine experience. Specifically, the median degree of satisfaction was 9 on a 10-point scale, with 10 being the highest level of satisfaction. Thus, our findings can be translatable to the routine setting in advanced prostate cancer practices and in accordance with published recommendations regarding the implementation and best practices of telemedicine in urology.12Rodriguez Socarras M. Loeb S. Teoh J.Y. et al.Telemedicine and smart working: recommendations of the European Association of Urology.Eur Urol. 2020; 78: 812-819Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar,13Gadzinski A.J. Gore J.L. Ellimoottil C. Odisho A.Y. Watts K.L. Implementing telemedicine in response to the COVID-19 pandemic.J Urol. 2020; 204: 14-16Crossref PubMed Scopus (88) Google Scholar Overall interest in and uptake of telemedicine among urologists have been observed as a result of the COVID-19 pandemic. A global survey of 620 urologists across 58 countries revealed that 81% of urologists who used telemedicine during the pandemic planned to continue doing so in the future, with 46% of all respondents reporting telemedicine use during the pandemic compared with only 16% before the pandemic. Notably, however, 68% of urologists surveyed in this study stated that at least half of their patient appointments should preferably be conducted in person.14Dubin J.M. Wyant W.A. Balaji N.C. et al.Telemedicine usage among urologists during the COVID-19 pandemic: cross-sectional study.J Med Internet Res. 2020; 22: e21875Crossref PubMed Scopus (45) Google Scholar With approximately 30% of the patients in our clinic agreeing to be seen through telemedicine, it is evident that many patients and providers still value and in some cases prefer in-person visits. Although studies are warranted to evaluate this within urology, patients may be unwilling to participate in telemedicine because of privacy concerns or the need for additional in-person tests or procedures. Similarly, urologists may prefer in-person visits because of the need for physical evaluations and tests or procedures in tandem with in-person appointments. Although we did not directly evaluate the barriers to telemedicine adoption, the global survey by Dubin et al14Dubin J.M. Wyant W.A. Balaji N.C. et al.Telemedicine usage among urologists during the COVID-19 pandemic: cross-sectional study.J Med Internet Res. 2020; 22: e21875Crossref PubMed Scopus (45) Google Scholar found that urologists reported patients’ lack of access to technology and patients’ technologic proficiency were the most cited barriers to telemedicine use. This finding suggests that to facilitate increased telemedicine use in urology, a greater emphasis should be placed on patient education and resources for telemedicine. Further studies are required.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,003
score de la tête « metaresearch » (Gemma)0,011
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMétarecherche
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,027
Score d'incertitude au seuil0,998

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0030,011
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0000,002
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,166
Tête enseignante GPT0,512
Écart entre enseignants0,347 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations11
Publié2021
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueMayo Clinic Proceedings Innovations Quality & OutcomesMême sujetCOVID-19 and healthcare impactsTravaux en français237 207